{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:40:45Z","timestamp":1777948845643,"version":"3.51.4"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2025-0034_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Pseudomyxoma peritonei (PMP) is a rare, slow-growing cancer with few efficacious treatment options in unresectable cases. Mutations in the\n                      <jats:italic>KRAS<\/jats:italic>\n                      and\n                      <jats:italic>GNAS<\/jats:italic>\n                      oncogenes are common, but the reported frequencies vary greatly, most likely because of low tumor cellularity in peritoneal tumor samples. With treatments targeting these mutations becoming increasingly available, reliable detection of mutations is essential.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2025-0034_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The frequency of\n                      <jats:italic>KRAS<\/jats:italic>\n                      and\n                      <jats:italic>GNAS<\/jats:italic>\n                      mutations was analyzed in tumor samples from 167 patients with verified PMP using targeted DNA sequencing and\/or droplet digital polymerase chain reaction. When analysis of fresh-frozen peritoneal tumor samples did not reveal mutations, macrodissected formalin-fixed samples were analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2025-0034_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mutations in cancer-related genes were detected in 98\u202f% of the analyzed samples, with\n                      <jats:italic>KRAS<\/jats:italic>\n                      and\n                      <jats:italic>GNAS<\/jats:italic>\n                      mutated in 148 (89\u202f%) and 139 (83\u202f%) cases, respectively. In 48\u202f% of the analyzed cases, the mutational diagnosis was based on primary tumor samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2025-0034_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      High frequencies of\n                      <jats:italic>KRAS<\/jats:italic>\n                      and\n                      <jats:italic>GNAS<\/jats:italic>\n                      mutations support the proposed role as driver mutations and as potential therapy targets. The primary tumor may serve as an alternative source of tumor material, increasing the likelihood of detecting targetable mutations. Combined with highly sensitive analytical methods, this approach facilitates selection of patients for novel targeted therapeutic strategies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2025-0034","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:55:35Z","timestamp":1765547735000},"page":"11-18","source":"Crossref","is-referenced-by-count":0,"title":["High prevalence of\n                    <i>KRAS<\/i>\n                    and\n                    <i>GNAS<\/i>\n                    mutations in pseudomyxoma peritonei underscores opportunities for targeted therapeutic strategies"],"prefix":"10.1515","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5751-9549","authenticated-orcid":false,"given":"Annette","family":"Torgunrud","sequence":"first","affiliation":[{"name":"Department of Tumor Biology , Norwegian Radium Hospital, Oslo University Hospital , Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christin","family":"Lund-Andersen","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology , Norwegian Radium Hospital, Oslo University Hospital , Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Davidson","sequence":"additional","affiliation":[{"name":"Department of Pathology , Oslo University Hospital , Oslo , Norway"},{"name":"Medical Faculty , Institute of Clinical Medicine, University of Oslo , Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina Katrine","family":"Nitschke Marcussen","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology , Norwegian Radium Hospital, Oslo University Hospital , Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stein G.","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , Norwegian Radium Hospital, Oslo University Hospital , Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vegar","family":"Dagenborg","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , Norwegian Radium Hospital, Oslo University Hospital , Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-0780","authenticated-orcid":false,"given":"Kjersti","family":"Flatmark","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology , Norwegian Radium Hospital, Oslo University Hospital , Oslo , Norway"},{"name":"Medical Faculty , Institute of Clinical Medicine, University of Oslo , Oslo , Norway"},{"name":"Department of Surgical Oncology , Norwegian Radium Hospital, Oslo University Hospital , Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2026050315471967560_j_pp-2025-0034_ref_001","doi-asserted-by":"crossref","unstructured":"Patrick-Brown, T, Mohamed, F, Thrower, A, Torgunrud, A, Cosyns, S, Canbay, E, et al.. Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei. Pleura Peritoneum 2023;8:1\u20139. https:\/\/doi.org\/10.1515\/pp-2022-0200.","DOI":"10.1515\/pp-2022-0200"},{"key":"2026050315471967560_j_pp-2025-0034_ref_002","doi-asserted-by":"crossref","unstructured":"Chua, TC, Moran, BJ, Sugarbaker, PH, Levine, EA, Glehen, O, Gilly, FN, et al.. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J\u00a0Clin Oncol 2012;30:2449\u201356. https:\/\/doi.org\/10.1200\/jco.2011.39.7166.","DOI":"10.1200\/jco.2012.30.4_suppl.532"},{"key":"2026050315471967560_j_pp-2025-0034_ref_003","doi-asserted-by":"crossref","unstructured":"Kusamura, S, Barretta, F, Yonemura, Y, Sugarbaker, PH, Moran, BJ, Levine, EA, et al.. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg 2021;156:e206363. https:\/\/doi.org\/10.1001\/jamasurg.2020.6363.","DOI":"10.1001\/jamasurg.2020.6363"},{"key":"2026050315471967560_j_pp-2025-0034_ref_004","doi-asserted-by":"crossref","unstructured":"S\u00f8rensen, O, Flatmark, K, Reed, W, Wiig, JN, Dueland, S, Giercksky, KE, et al.. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in pseudomyxoma peritonei. Eur J Surg Oncol 2012;38:969\u201376. https:\/\/doi.org\/10.1016\/j.ejso.2012.06.552.","DOI":"10.1016\/j.ejso.2012.06.552"},{"key":"2026050315471967560_j_pp-2025-0034_ref_005","doi-asserted-by":"crossref","unstructured":"Murage, NW, Ahmed, NM, Underwood, TJ, Walters, ZS, Breininger, SP. The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal mucinous neoplasms: a systematic review. Cancer Metastasis Rev 2023;42:335\u201359. https:\/\/doi.org\/10.1007\/s10555-023-10088-0.","DOI":"10.1007\/s10555-023-10088-0"},{"key":"2026050315471967560_j_pp-2025-0034_ref_006","doi-asserted-by":"crossref","unstructured":"Lund-Andersen, C, Torgunrud, A, Fleten, KG, Flatmark, K. Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review. J\u00a0Gastrointest Oncol 2021;12:S191\u2013s203. https:\/\/doi.org\/10.21037\/jgo-20-136.","DOI":"10.21037\/jgo-20-136"},{"key":"2026050315471967560_j_pp-2025-0034_ref_007","doi-asserted-by":"crossref","unstructured":"Nishikawa, G, Sekine, S, Ogawa, R, Matsubara, A, Mori, T, Taniguchi, H, et al.. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer 2013;108:951\u20138. https:\/\/doi.org\/10.1038\/bjc.2013.47.","DOI":"10.1038\/bjc.2013.47"},{"key":"2026050315471967560_j_pp-2025-0034_ref_008","doi-asserted-by":"crossref","unstructured":"Hara, K, Saito, T, Hayashi, T, Yimit, A, Takahashi, M, Mitani, K, et al.. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix. Pathol Res Pract 2015;211:657\u201364. https:\/\/doi.org\/10.1016\/j.prp.2015.06.004.","DOI":"10.1016\/j.prp.2015.06.004"},{"key":"2026050315471967560_j_pp-2025-0034_ref_009","doi-asserted-by":"crossref","unstructured":"Pengelly, RJ, Rowaiye, B, Pickard, K, Moran, B, Dayal, S, Tapper, W, et al.. Analysis of mutation and loss of heterozygosity by whole-exome sequencing yields insights into pseudomyxoma peritonei. J\u00a0Mol Diagn 2018;20:635\u201342. https:\/\/doi.org\/10.1016\/j.jmoldx.2018.05.002.","DOI":"10.1016\/j.jmoldx.2018.05.002"},{"key":"2026050315471967560_j_pp-2025-0034_ref_010","doi-asserted-by":"crossref","unstructured":"Gulay, KCM, Zhang, X, Pantazopoulou, V, Patel, J, Esparza, E, Pran Babu, DS, et al.. Dual inhibition of KRASG12D and Pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res 2023;83:3001\u201312. https:\/\/doi.org\/10.1158\/0008-5472.can-23-1313.","DOI":"10.1158\/0008-5472.CAN-23-1313"},{"key":"2026050315471967560_j_pp-2025-0034_ref_011","doi-asserted-by":"crossref","unstructured":"Skoulidis, F, Li, BT, Dy, GK, Price, TJ, Falchook, GS, Wolf, J, et al.. Sotorasib for lung cancers with KRAS p.G12C mutation. N\u00a0Engl J Med 2021;384:2371\u201381. https:\/\/doi.org\/10.1056\/nejmoa2103695.","DOI":"10.1056\/NEJMoa2103695"},{"key":"2026050315471967560_j_pp-2025-0034_ref_012","doi-asserted-by":"crossref","unstructured":"J\u00e4nne, PA, Riely, GJ, Gadgeel, SM, Heist, RS, Ou, SI, Pacheco, JM, et al.. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N\u00a0Engl J Med 2022;387:120\u201331. https:\/\/doi.org\/10.1056\/nejmoa2204619.","DOI":"10.1056\/NEJMoa2204619"},{"key":"2026050315471967560_j_pp-2025-0034_ref_013","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH. Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington cancer institute approach. Expet Opin Pharmacother 2009;10:1965\u201377. https:\/\/doi.org\/10.1517\/14656560903044974.","DOI":"10.1517\/14656560903044974"},{"key":"2026050315471967560_j_pp-2025-0034_ref_014","doi-asserted-by":"crossref","unstructured":"Carr, NJ, Cecil, TD, Mohamed, F, Sobin, LH, Sugarbaker, PH, Gonz\u00e1lez-Moreno, S, et al.. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the peritoneal surface oncology group international (PSOGI) modified delphi process. Am J Surg Pathol 2016;40:14\u201326. https:\/\/doi.org\/10.1097\/pas.0000000000000535.","DOI":"10.1097\/PAS.0000000000000535"},{"key":"2026050315471967560_j_pp-2025-0034_ref_015","doi-asserted-by":"crossref","unstructured":"Gibson, J, Pengelly, RJ, Mirandari, A, Boukas, K, Stanford, S, Cecil, TD, et al.. Targeted genetic sequencing analysis of 223 cases of pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy shows survival related to GNAS and KRAS status. Cancer Med 2024;13:e70340. https:\/\/doi.org\/10.1002\/cam4.70340.","DOI":"10.1002\/cam4.70340"},{"key":"2026050315471967560_j_pp-2025-0034_ref_016","doi-asserted-by":"crossref","unstructured":"Doll, J, Maurus, K, K\u00f6hler, F, Matthes, N, Lock, JF, Germer, CT, et al.. Molecular profiling of low-grade appendiceal mucinous neoplasms (LAMN). Genes Chromosomes Cancer 2024;63:e23270. https:\/\/doi.org\/10.1002\/gcc.23270.","DOI":"10.1002\/gcc.23270"},{"key":"2026050315471967560_j_pp-2025-0034_ref_017","doi-asserted-by":"crossref","unstructured":"Lin, YL, Zhu, JQ, Ma, RQ, Meng, W, Wang, ZY, Li, XB, et al.. Whole-exome sequencing identifies mutation profile and mutation signature-based clustering associated with prognosis in appendiceal pseudomyxoma peritonei. Mol Cancer Res 2024;22:70\u201381. https:\/\/doi.org\/10.1158\/1541-7786.mcr-22-0801.","DOI":"10.1158\/1541-7786.MCR-22-0801"},{"key":"2026050315471967560_j_pp-2025-0034_ref_018","doi-asserted-by":"crossref","unstructured":"Singhi, AD, Davison, JM, Choudry, HA, Pingpank, JF, Ahrendt, SA, Holtzman, MP, et al.. GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. Hum Pathol 2014;45:1737\u201343. https:\/\/doi.org\/10.1016\/j.humpath.2014.04.018.","DOI":"10.1016\/j.humpath.2014.04.018"},{"key":"2026050315471967560_j_pp-2025-0034_ref_019","doi-asserted-by":"crossref","unstructured":"Shetty, S, Thomas, P, Ramanan, B, Sharma, P, Govindarajan, V, Loggie, B. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. J\u00a0Surg Res 2013;180:97\u2013103. https:\/\/doi.org\/10.1016\/j.jss.2012.10.053.","DOI":"10.1016\/j.jss.2012.10.053"},{"key":"2026050315471967560_j_pp-2025-0034_ref_020","doi-asserted-by":"crossref","unstructured":"Pietrantonio, F, Perrone, F, Mennitto, A, Gleeson, EM, Milione, M, Tamborini, E, et al.. Toward the molecular dissection of peritoneal pseudomyxoma. Ann Oncol 2016;27:2097\u2013103. https:\/\/doi.org\/10.1093\/annonc\/mdw314.","DOI":"10.1093\/annonc\/mdw314"},{"key":"2026050315471967560_j_pp-2025-0034_ref_021","doi-asserted-by":"crossref","unstructured":"Wald, AI, Pingpank, JF, Ongchin, M, Hall, LB, Jones, H, Altpeter, S, et al.. Targeted next-generation sequencing improves the prognostication of patients with disseminated appendiceal mucinous neoplasms (Pseudomyxoma peritonei). Ann Surg Oncol 2023;30:7517\u201326. https:\/\/doi.org\/10.1245\/s10434-023-13721-y.","DOI":"10.1245\/s10434-023-13721-y"},{"key":"2026050315471967560_j_pp-2025-0034_ref_022","doi-asserted-by":"crossref","unstructured":"Wei, D, Wang, L, Zuo, X, Maitra, A, Bresalier, RS. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clin Cancer Res 2024;30:655\u201362. https:\/\/doi.org\/10.1158\/1078-0432.ccr-23-2098.","DOI":"10.1158\/1078-0432.CCR-23-2098"},{"key":"2026050315471967560_j_pp-2025-0034_ref_023","doi-asserted-by":"crossref","unstructured":"Wang, X, Allen, S, Blake, JF, Bowcut, V, Briere, DM, Calinisan, A, et al.. Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor. J\u00a0Med Chem 2022;65:3123\u201333. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01688.","DOI":"10.1021\/acs.jmedchem.1c01688"},{"key":"2026050315471967560_j_pp-2025-0034_ref_024","doi-asserted-by":"crossref","unstructured":"Kim, D, Herdeis, L, Rudolph, D, Zhao, Y, B\u00f6ttcher, J, Vides, A, et al.. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 2023;619:160\u20136. https:\/\/doi.org\/10.1038\/s41586-023-06123-3.","DOI":"10.1038\/s41586-023-06123-3"},{"key":"2026050315471967560_j_pp-2025-0034_ref_025","doi-asserted-by":"crossref","unstructured":"Holderfield, M, Lee, BJ, Jiang, J, Tomlinson, A, Seamon, KJ, Mira, A, et al.. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature 2024;629:919\u201326. https:\/\/doi.org\/10.1038\/s41586-024-07205-6.","DOI":"10.1038\/s41586-024-07205-6"},{"key":"2026050315471967560_j_pp-2025-0034_ref_026","doi-asserted-by":"crossref","unstructured":"Foote, JB, Mattox, TE, Keeton, AB, Chen, X, Smith, FT, Berry, K, et al.. A Pan-RAS inhibitor with a unique mechanism of action blocks tumor growth and induces antitumor immunity in gastrointestinal cancer. Cancer Res 2025;85:956\u201372. https:\/\/doi.org\/10.1158\/0008-5472.can-24-0323.","DOI":"10.1158\/0008-5472.CAN-24-0323"},{"key":"2026050315471967560_j_pp-2025-0034_ref_027","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez-Borrego, MC, Granados-Rodr\u00edguez, M, Bura, FI, Mart\u00ednez-L\u00f3pez, A, Rufi\u00e1n-And\u00fajar, B, Valenzuela-Molina, F, et al.. Antitumor effect of a small-molecule inhibitor of KRAS(G12D) in xenograft models of mucinous appendicular neoplasms. Exp Hematol Oncol 2023;12:102. https:\/\/doi.org\/10.1186\/s40164-023-00465-4.","DOI":"10.1186\/s40164-023-00465-4"},{"key":"2026050315471967560_j_pp-2025-0034_ref_028","doi-asserted-by":"crossref","unstructured":"Stanland, LJ, Huggins, HP, Sahoo, SS, Porrello, A, Chareddy, Y, Azam, SH, et al.. A first-in-class EGFR-directed KRAS G12V selective inhibitor. Cancer Cell 2025;43:1815\u201332. https:\/\/doi.org\/10.1016\/j.ccell.2025.05.016.","DOI":"10.1016\/j.ccell.2025.05.016"},{"key":"2026050315471967560_j_pp-2025-0034_ref_029","doi-asserted-by":"crossref","unstructured":"Weitz, J, Nishizaki, D, Liau, J, Patel, J, Ng, I, Sun, S, et al.. Cyclin-dependent kinase 4\/6 inhibition as a novel therapy for peritoneal mucinous carcinomatosis with GNAS mutations. J\u00a0Clin Oncol 2025;43:705\u201315. https:\/\/doi.org\/10.1200\/jco.24.00511.","DOI":"10.1200\/JCO.24.00511"},{"key":"2026050315471967560_j_pp-2025-0034_ref_030","doi-asserted-by":"crossref","unstructured":"Flatmark, K, Torgunrud, A, Fleten, KG, Davidson, B, Juul, HV, Mensali, N, et al.. Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei. J\u00a0Immunother Cancer 2021;9. https:\/\/doi.org\/10.1136\/jitc-2021-003109.","DOI":"10.1136\/jitc-2021-003109"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0034\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0034\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T20:59:36Z","timestamp":1777841976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0034\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,16]]},"published-print":{"date-parts":[[2026,3,19]]}},"alternative-id":["10.1515\/pp-2025-0034"],"URL":"https:\/\/doi.org\/10.1515\/pp-2025-0034","relation":{},"ISSN":["2364-7671","2364-768X"],"issn-type":[{"value":"2364-7671","type":"print"},{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}